Okay. I'm Bruno Paiva from the University of Navarra in Pamplona, Spain. I'm here at the IMS in Rio de Janeiro, and I have the privilege of talking about novel biomarkers such as circulating tumor cells or CTCs, as well as circulating tumor DNA or CTDNA. And I believe that these novel biomarkers will become more and more important to everyone in the field of myeloma, investigators, companies, and particularly the patients, because we have, I believe, a better understanding that if we want to predict outcomes, for example, of precursor conditions and doesn't smolder in myeloma, we need to monitor patients longitudinally over time with frequent testing and frequent testing does not, cannot request for multiple bone marrow aspects. And therefore we need minimally invasive markers such as CTCs and CTDNA to identify patients with stable versus evolving patterns. And the same concept applies to the field of MRD, measurable residual disease. Fortunately, patients are living longer and longer, either with treatment until disease progression, or even with fixed duration therapy. However, the longer periods cannot be intrinsically related with more and more bone marrow aspirates to measure depth of response. We must measure depth of response in the peripheral blood and serum. And this is why again, these novel biomarkers hopefully will become more and more informative and more and more used in both clinical trials and routine practice.